Diane Havlir
Expertise in
6
conditions

Dr. Diane Havlir

Infectious Disease
University Of California San Francisco
995 Potrero Ave Bldg 80, 
San Francisco, CA 
Expertise in
6
conditions
University Of California San Francisco
995 Potrero Ave Bldg 80, 
San Francisco, CA 

Overview

Diane Havlir is an Infectious Disease provider in San Francisco, California. Dr. Havlir is highly rated in 6 conditions, according to our data. Her top areas of expertise are HIV/AIDS, Malaria, Sepsis, and COVID-19.

Her clinical research consists of co-authoring 342 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

University of California San Francisco
995 Potrero Ave Bldg 80, San Francisco, CA 94110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Enrollment Status: Terminated
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
Enrollment Status: Completed
Publish Date: February 06, 2018
View 8 Less Clinical Trials

342 Total Publications

Youths' strategies for HIV status disclosure in rural Kenya and Uganda: You can't just trust everyone".
Youths' strategies for HIV status disclosure in rural Kenya and Uganda: You can't just trust everyone".
Journal: SSM. Qualitative research in health
Published: January 19, 2026
Similar Doctors
Expertise in
18
conditions
Dr. Angelle Labeaud
Infectious Disease
Expertise in
18
conditions
Dr. Angelle Labeaud
Infectious Disease

Lucile Packard Children's Hospital Stanford

725 Welch Rd, 
Palo Alto, CA 
 (25.5 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Angelle Labeaud is an Infectious Disease provider in Palo Alto, California. Dr. Labeaud is highly rated in 18 conditions, according to our data. Her top areas of expertise are Viral Hemorrhagic Fever, Arbovirosis, Dengue Fever, and Togaviridae Disease.

Expertise in
4
conditions
Dr. Michael Peluso
Infectious Disease
Expertise in
4
conditions
Dr. Michael Peluso
Infectious Disease

University Of California San Francisco

995 Potrero Ave, 
San Francisco, CA 
 (0.1 miles away)
628-206-2400
Languages Spoken:
English
See accepted insurances

Michael Peluso is an Infectious Disease provider in San Francisco, California. Dr. Peluso is highly rated in 4 conditions, according to our data. His top areas of expertise are Long Haul COVID, HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), and COVID-19.

Expertise in
4
conditions
Dr. Bryan Greenhouse
Infectious Disease
Expertise in
4
conditions
Dr. Bryan Greenhouse
Infectious Disease

San Francisco VA Medical Center

4150 Clement St, 
San Francisco, CA 
 (5.6 miles away)
415-221-4810
Languages Spoken:
English

Bryan Greenhouse is an Infectious Disease provider in San Francisco, California. Dr. Greenhouse is highly rated in 4 conditions, according to our data. His top areas of expertise are Malaria, Sepsis, Long Haul COVID, and Severe Acute Respiratory Syndrome (SARS).

Frequently Asked Questions about Dr. Diane Havlir

How do I make an appointment with Dr. Diane Havlir?

You can book an appointment with Dr. Diane Havlir by calling their office at 415-476-4082. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Diane Havlir a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Diane Havlir is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Diane Havlir specialize in?

While Dr. Diane Havlir is a Infectious Disease, they have specific expertise in HIV/AIDS, Malaria, and Sepsis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Diane Havlir participate in research or clinical trials?

Yes. Dr. Diane Havlir has published 342 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Diane Havlir's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Diane Havlir accept my insurance?

Dr. Diane Havlir accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 415-476-4082 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Havlir's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile